OR-POWIN
7.5.2024 15:01:37 CEST | Business Wire | Press release
Global energy storage platform provider Powin LLC (Powin) today announced its new multi-cell-based hardware platform, the Powin Pod (Pod). Designed for utility-scale projects, Pod takes Powin’s battery energy storage system (BESS) technology to the next level, setting a new standard for energy storage solutions with higher energy density, top-tier safety, reliability and enhanced cost savings. The Pod platform complements Powin's Centipede product line, offering a comprehensive suite of solutions to meet diverse customer requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507995695/en/
Powin's new multi-cell-based hardware platform, the Powin Pod. (Photo: Business Wire)
"We consistently challenge ourselves to improve our products and services to ensure we are continuously delivering nothing short of excellence to both new and existing customers," said Jeff Waters, CEO of Powin. "This next-generation product advancement demonstrates our commitment to bringing the safest and highest quality energy storage solutions to the market, advancing the entire industry as a result."
The new Pod platform is part of a fully integrated Powin energy storage solution that includes an end-to-end offering—spanning StackOS software, system design, delivery, commissioning and long-term service—that will enable Powin to meet growing customer needs with an improved, reliable and energy-dense storage platform. Powin’s proprietary Battery Management System and Energy Management controls comply with robust localized cybersecurity standards and regulations, ensuring superior protection for data privacy and intellectual property, guaranteeing security of customers’ data, operations and investment at all times. Customers who select Pod will benefit from Powin's full authorization to perform long-term services at their site, as well as comprehensive system training from the company. Within a fully integrated solution, Powin delivers safety, availability, insight and flexibility, providing lower risk, enhanced performance and improved revenue generation.
The Powin Pod platform offers benefits such as:
- Higher-density energy storage: Upgraded cell capacity, utilization of cell-to-pack technology and optimized internal space maximizes energy density and results in significant land savings for projects. Powin Pod delivers a 50% increase in energy density from the Powin Centipede platform. This solution and density improvement is available at 2-hour or greater system applications.
- Top-tier safety and reliability: Liquid cooling provides more stable internal battery system temperatures, ensuring enhanced system safety and longevity. Powin complies with the latest and most stringent fire prevention standards such as UL9540A, NFPA 68 and NFPA 69, while having optional class-leading fire suppression at module and container level.
- Enhanced cost savings: Powin Pod’s compact size reduces the amount of land required for installation, and Powin’s faster and lower cost shipping and on-time delivery combined with simplified installation and commissioning processes allow for lower CAPEX and greater customer savings.
With a proven track record of over 17 GWh deployed and under construction worldwide and over six million battery cells monitored, Powin is a trusted and established US-based integrator. Powin provides world-class logistics for on-time delivery, 20-year performance guarantee and long-term service structures and relies on a 24/7 Remote Operations Center and over 500 field service technicians and Authorized Service Providers to ensure optimal system performance.
Powin Pod is now available to order in markets globally and delivery is expected to begin in mid-2025. Starting in 2026, Powin Pod will be manufactured in the US complying with US Domestic Content requirements. To learn more about Powin’s latest product advancements, please visit https://powin.com/powin-pod/ or visit the Powin team at CLEANPOWER 2024 at booth #2645.
About Powin, LLC (Powin)
At Powin, we are advancing the next frontier of energy and changing the way we power our daily lives by ensuring access to clean, resilient, and affordable power. As a global energy storage platform provider, we offer fully integrated battery solutions, software, and services to optimize grid performance and enable the transition to cleaner energy sources. To learn more, please visit www.powin.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507995695/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom